The Food and Drug Administration announced Thursday it had authorized molnupiravir, a drug produced by Merck and Ridgeback Biotherapeutics, to treat some American adults with COVID-19 who are at risk ...
Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...
The Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to 2 oral antiviral therapies for COVID-19. Concise drug information for molnupiravir and Paxlovid is provided ...
One day after authorizing Pfizer's COVID-19 treatment pills, the US Food and Drug Administration on Thursday cleared a second pill -- this one from Merck -- for treating the virus under the agency's ...
One of the biggest concerns at the Nov. 30 meeting of the FDA’s Antimicrobial Drugs Advisory Committee is that, if Merck & Co. Inc.-Ridgeback Biotherapeutics Inc.’s antiviral drug, molnupiravir, is ...
In this Q&A, Erica Johnson, MD, provides insight into the new oral antiviral medications that may soon be approved for the treatment of COVID-19. The Food and Drug Administration (FDA) may soon ...
One of the biggest concerns at the Nov. 30 meeting of the FDA’s Antimicrobial Drugs Advisory Committee is that, if Merck & Co. Inc.-Ridgeback Biotherapeutics Inc.’s antiviral drug, molnupiravir, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results